JNJ Quantitative Stock Analysis

Johnson & Johnson (JNJ) has received an 88% rating from Validea's P/B Growth Investor model, which is based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained future growth potential. As a large-cap growth stock in the Biotechnology & Drugs industry, JNJ largely satisfies the model's criteria, passing most tests with the exception of Research and Development to Assets. This 88% score indicates 'some interest' from the strategy, which is notable given Mohanram's academic work on growth models that have demonstrated market outperformance.

Analysis

Johnson & Johnson (JNJ) has been identified as a compelling large-cap growth stock, scoring 88% on Validea's P/B Growth Investor model, a framework based on the academic work of Partha Mohanram. This score indicates significant alignment with a strategy designed to find low book-to-market stocks with fundamentals supporting sustained growth. JNJ demonstrates robust financial health by passing key model criteria, including Return on Assets, Cash Flow from Operations to Assets, and stability metrics such as low variance in both ROA and sales. This suggests strong profitability and operational efficiency. The single point of weakness highlighted by the model is the company's Research and Development to Assets ratio, which it failed. For a firm in the Biotechnology & Drugs industry, where innovation is a primary growth driver, this specific metric is a notable counterpoint to the otherwise positive fundamental assessment.

Key Decisions for Investors

• Given the stock's high score on a proven growth model and strong underlying fundamentals like ROA and cash flow, growth-oriented investors may view this as a positive signal warranting further consideration for inclusion in a portfolio.
• Investors must critically investigate the single identified weakness, the low Research and Development to Assets ratio, to assess whether it signals a potential long-term risk to JNJ's innovation pipeline and competitive positioning.
• This quantitative analysis should serve as a screening tool, prompting deeper due diligence into the qualitative aspects of JNJ's business and its standing relative to industry peers before making any capital allocation decisions.